World's Best Scientists 2026 revealed!
Anders Österborg

Anders Österborg

D-Index & Metrics

Medicine

D-Index
80
Citations
23991
World Ranking
17091
National Ranking
324

Anders Österborg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anders Österborg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 371 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anders Österborg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anders Österborg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anders Österborg is affiliated with the Karolinska Institute in Sweden and has an extensive body of research primarily within the field of medicine. Their work spans multiple subfields including genetics, immunology, pathology and forensic medicine, infectious diseases, and oncology. The main focus of Österborg's research involves chronic lymphocytic leukemia, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, as well as SARS-CoV-2 and COVID-19 clinical research.

Their frequent publication venues include Blood, Clinical Lymphoma Myeloma & Leukemia, Haematologica, EBioMedicine, and the Journal of Clinical Oncology.

Frequent coauthors collaborating with Österborg include Lotta Hansson, Martin Šimkovič, Tadeusz Robak, Marcus Buggert, and Constantine S. Tam.

Representative recent papers by Österborg cover significant topics in hematology and infectious diseases. These include:

  • "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia," 2022, New England Journal of Medicine
  • "Outcomes of COVID-19 in patients with CLL: a multicenter international experience," 2020, Blood
  • "Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial," 2022, The Lancet Oncology
  • "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial," 2021, EBioMedicine
  • "Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities," 2022, NEJM Evidence

The main topics addressed in Österborg's work are:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research

The subfields of study associated with their publications include:

  • Genetics
  • Immunology
  • Pathology and Forensic Medicine
  • Infectious Diseases
  • Oncology

Österborg's research contributes to an understanding of hematological malignancies and immunological conditions across clinical and translational domains, with a notable emphasis on therapeutic strategies and responses to infectious diseases in immunocompromised populations.

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

    Jeanette Lundin;Eva Kimby;Magnus Björkholm;Per-Anders Broliden

  • Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

    Francesco D'Amore;Thomas Relander;Grete F. Lauritzsen;Esa Jantunen

  • Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

    A. Österborg;M. J. S. Dyer;D. Bunjes;G. A. Pangalis

  • Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

    Jeanette Lundin;Hans Hagberg;Roland Repp;Eva Cavallin-Ståhl

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

    C. Bokemeyer;M.S. Aapro;A. Courdi;J. Foubert

  • A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

    Gunilla Enblad;Hans Hagberg;Martin Erlanson;Jeanette Lundin

  • Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

    Eva Hellström-Lindberg;Tomas Ahlgren;Yves Beguin;Magnus Carlsson

  • Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

    Susan O'Brien;Susan O'Brien;Jeffrey A Jones;Steven E Coutre;Anthony R Mato;Anthony R Mato

  • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

    J Lundin;Anders Osterborg;G Brittinger;Derek Crowther

  • EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

    C. Bokemeyer;M.S. Aapro;A. Courdi;J. Foubert

  • Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

    Anders ÖSterborg;Athanasios S. Fassas;Achilles Anagnostopoulos;Martin J. S. Dyer

  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

    Anthony R. Mato;Lindsey E. Roeker;Nicole Lamanna;John N. Allan

  • Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

    A Osterborg;MA Boogaerts;R Cimino;U Essers

  • Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses

    Anders Österborg;Qing Yi;Lotta Henriksson;Jan Fagerberg

  • Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

    Geoff Hale;Peppy Rebello;Lee R. Brettman;Chris Fegan

  • Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†

    Aapro M;Beguin Y;Bokemeyer C;Dicato M

  • Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.

    Youn H. Kim;Madeleine Duvic;Erik Obitz;Robert Gniadecki

  • Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

    Amir H. DaneshManesh;Eva Mikaelsson;Mahmood Jeddi‐Tehrani;Ali Ahmad Bayat

Frequent Co-Authors

Håkan Mellstedt
Håkan Mellstedt Karolinska Institute
Mahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani Avicenna Research Institute
Magnus Björkholm
Magnus Björkholm Karolinska University Hospital
Peter Hillmen
Peter Hillmen St James's University Hospital
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Heinz Ludwig
Heinz Ludwig University of Vienna
Martin J. S. Dyer
Martin J. S. Dyer University of Leicester
Qing Yi
Qing Yi Houston Methodist
Bo Nilsson
Bo Nilsson Uppsala University
Yves Beguin
Yves Beguin University of Liège

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career in the USA, a wide range of online health degrees can expand your options. For those interested in healthcare leadership, explore the most affordable online mha programs to build management skills and improve your career prospects.

Advanced practice nurses may want to consider the most affordable online dnp programs, giving you flexibility to further your expertise while balancing work and family commitments.

Interested in the pharmaceutical field? Learn more about online pharmacy school cost to plan your financial investment and choose the best program for your goals.

Finally, for students who want to work at the intersection of health and technology, a health information management degree online can lead to dynamic careers in a rapidly growing sector. Each pathway has its own unique requirements, costs, and career outcomes, so explore your options to find the best fit for your future.

Best Scientists Citing Anders Österborg

Trending Scientists

Recently Published Articles